HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

483.837

-12.921-2.60%

Number of Gainers:6

Number of Losers:25

Number of Flat:2

PE:- -

High:496.758

Open:496.758

Low:480.418

Close:496.758

Volume:63.19M

Turnover:1.50B

Market Cap:307.02B

Float Cap:273.75B

Loading ...

KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions

THOMSON REUTERS

KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection

THOMSON REUTERS

OCUMENSION-B Completes Patient Enrollment in Phase III Trial of Dry Eye Treatment

Ocumension Completes Enrollment in China Phase III Trial of Dry Eye Drug OT-211

REMEGEN Discloses Cumulative Buyback of 41,000 A-Shares by End of August

Executive Director Wang Yuxiao Reduces Stake in Remegen (09995) by 13,500 Shares at Approximately HK$81.54 Each

Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects

GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd

HBM Holdings Says Dr. Yiping Rong Resigns as Executive Director to Focus on Other Commitments

AH Premium Rankings for September 2nd Market Close

Shinva Medical Secures Class II and III Device Approvals for Advanced Radiotherapy and Thoracoscopic Systems

港股动态：今海医疗科技股价攀升逾4%，中期收益激增逾1.3倍，核心业务向高附加值医疗器械领域转型

CSTONE PHARMA-B (02616) climbs over 4% in early trade; sales surge after listing in state medical insurance

Zai Lab Surges on Global Phase III Trial Launch for Frontline Small Cell Lung Cancer

歌礼制药-B股价早盘攀升逾8%，重磅减肥药全球III期试验迎来关键里程碑

Betta Pharma's Hong Kong IPO: A Profit Pioneer Faces Patent Cliffs and Pipeline Doubts

Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted by NMPA

US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy

Ocumension Therapeutics' Application for Ocular Inflammation Drug Accepted in China

MT Newswires Live

Ocumension Therapeutics - Application for Dexamethasone Intraocular Suspension Accepted by Nmpa as Class 4 Chemical Drug

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/BK1574/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":483.83676,"timestamp":1789104261513,"preClose":496.75812,"halted":0,"volume":63190961,"delay":0,"changeRate":-0.026011,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-12.921356,"latestTime":"09-11 13:24:22","open":496.75812,"high":496.75812,"low":480.41833,"amount":1499192181,"amplitude":0.032893,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789114200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.703217,"peRate":164.740195,"turnoverRate":0.002405,"increases":6,"decrements":25,"flats":1,"marketCap":307020944560,"floatMarketCap":273753246024},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.032893,"preClose":496.75812,"low":480.41833,"pbRate":"3.703217","latestPrice":483.83676,"volume":63190961,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.002405,"peRate":164.740195,"marketCap":307020944560,"floatMarketCap":273753246024,"timestamp":1789104261513,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664814417","title":"KeyMed Biosciences - Aeira Responsible for Registration and Commercialization of Stapokibart Injection in 18 Countries and Regions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664814417","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664814417?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1587","BK1574","BK1583","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664144128","title":"KeyMed Biosciences - Enters Exclusive Licensing Agreement with Aeira Pte for Stapokibart Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2664144128","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664144128?lang=en_us&edition=fundamental","pubTime":"2026-09-02 21:04","pubTimestamp":1788354266,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44T1AZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1587","BK1574","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126045427","title":"OCUMENSION-B Completes Patient Enrollment in Phase III Trial of Dry Eye Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1126045427","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126045427?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:16","pubTimestamp":1788351373,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has announced the completion of patient enrollment for its Phase III clinical trial of OT-211 (TRYPTYR® acotiamide eye drops) in the People's Republic of China, with a total of...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBJ","PSYK","BK1191","IBBQ","BK1574","01477","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811874","title":"Ocumension Completes Enrollment in China Phase III Trial of Dry Eye Drug OT-211","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811874","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811874?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:13","pubTimestamp":1788351237,"startTime":"0","endTime":"0","summary":"Ocumension completes enrollment in China Phase III trial of dry eye drug OT-211Ocumension Therapeutics completed patient enrollment in a Phase III China trial of OT-211 for dry eye disease.Results hav","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDLbTKXg6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118027728","title":"REMEGEN Discloses Cumulative Buyback of 41,000 A-Shares by End of August","url":"https://stock-news.laohu8.com/highlight/detail?id=1118027728","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118027728?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:04","pubTimestamp":1788350652,"startTime":"0","endTime":"0","summary":"REMEGEN (09995) has released an announcement detailing its share repurchase activities.As of August 31, 2026, the company had repurchased a cumulative total of 41,000 A-shares through the Shanghai...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","399300","LU2148510915.USD","83188","LU1969619763.USD","BK1161","83130","07233","159982","02827","LU2328871848.SGD","03130","688331","LU1064131003.USD","82846","03188","02846","BK1583","09995","LU2488822045.USD","BK1147","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164591890","title":"Executive Director Wang Yuxiao Reduces Stake in Remegen (09995) by 13,500 Shares at Approximately HK$81.54 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1164591890","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164591890?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:46","pubTimestamp":1788349577,"startTime":"0","endTime":"0","summary":"According to the latest disclosures from the Hong Kong Stock Exchange, on August 27, executive director Wang Yuxiao sold 13,500 shares of Remegen (09995) at an average price of HK$81.5352 per share,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU1969619763.USD","09995","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","BK0239","BK1574","EWH","LU2488822045.USD","LU1064131003.USD","BK1161","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149967319","title":"Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects","url":"https://stock-news.laohu8.com/highlight/detail?id=1149967319","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149967319?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:44","pubTimestamp":1788349448,"startTime":"0","endTime":"0","summary":"To advance high-quality development in the medical device industry and uncover promising local innovations, the Shenzhen Municipal Market Supervision Administration recently organized a roadshow and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","159883","LNGR","BK1583","RSPH","IEIH","BK1574","HART","MEDX","GDOC","MDEV","PTH","BK1100","LGHT","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186482960","title":"GENFLEET-B Allocates HK$1.08 Million to Buy Back Shares on September 2nd","url":"https://stock-news.laohu8.com/highlight/detail?id=1186482960","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186482960?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:08","pubTimestamp":1788347291,"startTime":"0","endTime":"0","summary":"On September 2nd, GENFLEET-B (02595) announced a share repurchase, investing approximately HK$1.0763 million to buy back 39,000 shares.The buyback was conducted at a total cost of HK$1.0763 million, reflecting the company's capital management strategy and its view on the current market valuation.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","BK1574","BK1515","02595","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664892082","title":"HBM Holdings Says Dr. Yiping Rong Resigns as Executive Director to Focus on Other Commitments","url":"https://stock-news.laohu8.com/highlight/detail?id=2664892082","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664892082?lang=en_us&edition=fundamental","pubTime":"2026-09-02 16:33","pubTimestamp":1788338000,"startTime":"0","endTime":"0","summary":"HBM Holdings says Dr. Yiping Rong resigns as executive director to focus on other commitmentsHBM issued a supplemental clarification on the Aug. 27 management changes.Executive director Yiping Rong resigned to reallocate time to other business commitments.All other details in the Aug. 27 announcement remain unchanged, with the changes effective Aug. 27.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on September 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL8nk3b1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186234493","title":"AH Premium Rankings for September 2nd Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1186234493","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186234493?lang=en_us&edition=fundamental","pubTime":"2026-09-02 16:21","pubTimestamp":1788337316,"startTime":"0","endTime":"0","summary":"According to data released at the close of trading on September 2nd, NE ELECTRIC (00042), ZHEJIANG SHIBAO (01057), and HOLLY FUTURES (03678) occupy the top three positions in the A-H share premium...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1122","LU2476274308.USD","LU1719994722.HKD","HK0000306685.HKD","LU1655091616.SGD","LU0287142896.SGD","HK0000352291.HKD","LU0516422952.EUR","LU0329678337.USD","BK1594","LU0164939612.USD","LU0417516902.SGD","HK0001040143.USD","BK1533","LU0165289439.USD","LU0210526637.USD","LU0164880469.USD","IE00BZ08YT58.USD","LU2294711473.HKD","LU0096374516.USD","LU0890818403.SGD","LU0708995583.HKD","LU0469268626.HKD","BK1191","LU0048580855.USD","BK1202","LU1023057109.AUD","HK0000320223.HKD","LU0082770016.USD","01057","LU1328277881.USD","LU1211504680.USD","LU0320764599.SGD","LU1688375341.USD","BK1523","LU0589944569.HKD","LU0072913022.USD","BK1576","83130","BK1562","02475","LU0128522157.USD","IE00BYV24P56.USD","LU0531970944.HKD","HK0001040168.HKD","BK1231","LU0516423174.USD","02338","BK1507","LU2097828557.USD","LU1303224171.USD","03328","LU1961090484.USD","IE00BF5LJ272.USD","IE00B3M56506.USD","00668","LU1152091754.HKD","BK1521","LU0431992006.USD","LU2226246903.HKD","LU2045819591.USD","LU0149534421.HKD","LU0791591158.USD","LU0228367735.SGD","LU0228659784.USD","82846","LU1813983027.USD","LU0516423091.SGD","02359","00568","IE00B031HY20.USD","LU0327786744.USD","LU1988902786.USD","LU0572944931.SGD","BK1190","LU2177674079.SGD","LU2097828714.EUR","LU0229945570.USD","00300","LU2778985437.USD","LU1046422090.SGD","BK1141","159982","LU1831875114.USD","BK1249","LU1244550221.USD","03986","LU0456854461.SGD","LU1282649067.USD","00991","LU0254981946.USD","SG9999002463.SGD","03678","HK0000306701.USD","LU0211977185.USD","00553","BK1116","LU0823426480.USD","01108","IE00BGHQDM52.EUR","03188","LU0051755006.USD","LU0348816934.USD","SG9999001226.SGD","LU0588546209.SGD","LU0821914370.USD","BK1561","LU0049853897.USD","LU0149721374.USD","06826","BK1125","BK1610","LU0593848301.USD","LU2008162690.USD","LU1366334578.USD","LU0266512473.USD","BK1593","LU0163747925.USD","SG9999006597.SGD","LU1282649141.HKD","BK1214","LU0117841782.USD","07233","LU0880133367.SGD","LU0417516738.SGD","IE00BVYPNP33.GBP","LU0871576103.HKD","BK1506","LU0620787316.HKD","02827","LU0640798160.USD","LU1675838814.USD","LU0244354667.USD","IE0034224299.USD","LU1242518857.USD","LU2242644610.SGD","IE0008369823.USD","02218","BK1193","LU1226287529.USD","01812","LU0886674414.USD","IE00B031J352.USD","02846","LU0348766576.USD","LU1880383440.USD","LU0106252389.USD","SG9999001093.SGD","IE00B0169L03.USD","LU0348805143.USD","LU0348788117.USD","LU0181495838.USD","LU0359201885.HKD","LU0348814723.USD","BK1186","06613","LU1224709979.USD","LU0164865239.USD","LU0320764755.SGD","BK1530","LU1152091168.USD","06185","LU2394011477.USD","IE00B29SXG58.USD","LU0543330566.HKD","LU0737861772.HKD","BK1105","83188","BK1522","BK1183","LU1282648689.USD","LU2097828805.USD","LU1064131342.USD","LU0384037296.USD","LU0501845795.SGD","BK1171","LU1504937902.USD","03143","03296","LU0488056044.USD","LU0315179316.USD","LU0329678170.USD","IE00BVYPNQ40.USD","01877","BK1144","IE00B5MMRT66.SGD","LU1048596156.SGD","HK0000352382.USD","LU0039217434.USD","LU0140636845.USD","LU0067412154.USD","LU0370786039.SGD","LU1720050803.USD","LU0345780521.USD","03968","LU1960683339.HKD","LU0456827905.SGD","LU0791590937.USD","LU0463099449.HKD","LU0043850808.USD","LU0828237510.HKD","00187","06869","LU0918141705.HKD","02701","LU3063872942.SGD","02899","BK1163","LU2097828631.EUR","LU0348767384.USD","EWH","LU0455707207.USD","LU0516422440.USD","BK1560","LU1244550577.SGD","399300","LU0561508036.HKD","LU2399975544.HKD","LU0214875030.USD","LU1242518931.SGD","BK1170","SG9999002828.SGD","LU0648948544.HKD","LU0456846285.SGD","BK1505","BK1237","LU0449509016.USD","LU0359201612.USD","BK1149","LU0348827113.USD","IE00BZ08YS42.EUR","LU0979878070.USD","LU1188198961.HKD","LU0266512127.USD","BK1546","LU1770034418.SGD","LU0106959298.USD","LU0634319403.HKD","LU0345780281.USD","LU0828237940.HKD","IE00B543WZ88.USD","03750","BK1551","BK1147","LU0828238088.HKD","LU0607220059.USD","00981","LU0516422366.SGD","03130","LU1769817179.HKD","LU0868486357.SGD","LU1769817096.USD","LU1366334651.USD","BK1554","LU0082770016.SGD","BK1123","03308","LU0326950275.SGD","BK1583","BK1515","SG9999014674.SGD","LU1481107354.HKD","LU0543330483.HKD","LU0307460666.USD","LU0269904917.USD","LU0672654166.SGD","BK1614","LU0359202008.SGD","LU0502904849.HKD","00042","LU0797268264.HKD","LU1880383366.USD","LU0328353924.USD","BK1607","BK1544","BK1564","LU0231483743.USD","LU0314109678.HKD","LU1008478684.HKD","LU2476274720.SGD","LU1244550494.USD","BK1592","IE00BZ08YR35.GBP","LU1255011170.USD","IE00BMCWC346.EUR","LU1807302812.USD","01055","LU1808992512.USD","BK1574","LU0052750758.USD","BK1526","LU0509642566.USD","LU0540923850.HKD","LU1282649810.SGD","HK0000320264.USD","LU2039709279.SGD","LU0862451753.SGD","LU0918141887.USD","03759","BK1514","LU1993786604.SGD","BK1198","LU0061477393.USD","LU0348735423.USD","LU1794554557.SGD","BK1223","LU2264538146.SGD","LU1251922891.USD","SG9999004220.SGD","LU0173614495.USD","IE0008368742.USD","LU0029875118.USD","IE0032431581.USD","SG9999011746.SGD","LU0823426308.USD","IE0031814852.USD","LU2097828474.EUR","01033","LU0737861699.HKD","LU1115378108.SGD","LU2125910500.SGD","06821","LU0531971595.HKD","LU1105468828.SGD","01349","BK1161","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186287506","title":"Shinva Medical Secures Class II and III Device Approvals for Advanced Radiotherapy and Thoracoscopic Systems","url":"https://stock-news.laohu8.com/highlight/detail?id=1186287506","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186287506?lang=en_us&edition=fundamental","pubTime":"2026-09-02 15:51","pubTimestamp":1788335497,"startTime":"0","endTime":"0","summary":"Shinva Medical Instrument Co.,Ltd. (600587.SH) has announced that it recently received the Medical Device Registration Certificate from China's National Medical Products Administration, while its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HART","BK0188","600587","MDEV","BK1583","IEIH","AGNG","BK1574","LGHT","BK1100","RSPH","LNGR","MEDX","BK0251","PTH","159883","GDOC","BK0028","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184201272","title":"港股动态：今海医疗科技股价攀升逾4%，中期收益激增逾1.3倍，核心业务向高附加值医疗器械领域转型","url":"https://stock-news.laohu8.com/highlight/detail?id=1184201272","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184201272?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:10","pubTimestamp":1788329416,"startTime":"0","endTime":"0","summary":"今海医疗科技（02225）股价今日表现活跃，盘中涨幅一度超过5%。截至最新交易时段，该股上涨4.08%，报4.72港元，成交额达628.74万港元。据近期披露的2026年中期业绩显示，公司在营收扩张与盈利质量方面均呈现积极态势。报告期内，集团实现收益3402.1万新加坡元，较去年同期大幅增长134.16%，彰显出强劲的销售增长动能。从业务结构来看，2026年上半年，公司收入构成实现显著优化，战略重...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1583","BK4588","MEDX","PTH","AGNG","BK4585","VXUS","RSPH","IEIH","BK1150","MDEV","GDOC","LNGR","HART","KCAI","02225","159883","BK1574","LGHT","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153382675","title":"CSTONE PHARMA-B (02616) climbs over 4% in early trade; sales surge after listing in state medical insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=1153382675","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153382675?lang=en_us&edition=fundamental","pubTime":"2026-09-02 11:48","pubTimestamp":1788320896,"startTime":"0","endTime":"0","summary":"CSTONE PHARMA-B (02616) saw its share price jump more than 4% during Tuesday morning trading. At the time of writing, the stock was up 4.73% at HK$5.975, with trading turnover reaching HK$11.53...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","VXUS","KCAI","02616","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146523371","title":"Zai Lab Surges on Global Phase III Trial Launch for Frontline Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1146523371","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146523371?lang=en_us&edition=fundamental","pubTime":"2026-09-02 10:21","pubTimestamp":1788315694,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd (09688) shares climbed more than 6% in early trading on Wednesday. As of writing, the stock was up 5.97% at HK$20.60, with turnover reaching HK$59.68 million.On August 31, the company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","BK1161","BK4588","BK4531","BK1574","BK4139","LU2488822045.USD","09688","BK4548","BK1588","ZLAB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192195245","title":"歌礼制药-B股价早盘攀升逾8%，重磅减肥药全球III期试验迎来关键里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1192195245","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192195245?lang=en_us&edition=fundamental","pubTime":"2026-09-02 10:21","pubTimestamp":1788315673,"startTime":"0","endTime":"0","summary":"歌礼制药-B（01672）今日早盘表现强劲，股价涨幅超过8%。截至发稿时，该股上涨8.07%，报10.31港元，成交额达926.46万港元。该公司近日发布公告，其专有的每日一次口服小分子胰高血糖素样肽-1受体（GLP-1R）激动剂ASC30，用于长期体重管理的全球III期临床项目已顺利完成首例受试者给药。该药物目前正处于临床研究阶段，旨在开发用于长期体重管理及糖尿病治疗。根据公告披露，歌礼制药-B...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1161","01672","BK1574","01477","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185564913","title":"Betta Pharma's Hong Kong IPO: A Profit Pioneer Faces Patent Cliffs and Pipeline Doubts","url":"https://stock-news.laohu8.com/highlight/detail?id=1185564913","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185564913?lang=en_us&edition=fundamental","pubTime":"2026-09-02 09:20","pubTimestamp":1788312055,"startTime":"0","endTime":"0","summary":"After a five-year hiatus, Betta Pharmaceuticals Co., Ltd. is once again knocking on the doors of the Hong Kong stock exchange, carrying the mantle of being the \"first domestic innovative targeted...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","REDS","FRHC","LNGR","159992","IPOS","MEDX","BK0060","BK0239","IBBQ","KCE","300558","BK1574","BK4127","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664868365","title":"Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2664868365","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664868365?lang=en_us&edition=fundamental","pubTime":"2026-09-02 00:08","pubTimestamp":1788278881,"startTime":"0","endTime":"0","summary":"Sept 1 (Reuters) - Ocumension Therapeutics <1477.HK>::*APPLICATION FOR DEXAMETHASONE INTRAOCULAR SUSPENSION ACCEPTED BY NMPA AS CLASS 4 CHEMICAL DRUG*Further company coverage: 1477.HK* ((Reuters.Brief","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nRSD1PwvSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148610163","title":"US Stock Alert: Novartis Gains 5% On Positive Late-Stage Trial Results For MS Oral Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1148610163","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148610163?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:00","pubTimestamp":1788271219,"startTime":"0","endTime":"0","summary":"On Tuesday, shares of Novartis AG (NVS.US) climbed more than 5% to trade at $160.82 apiece. The surge follows the company's announcement that its investigational oral therapy, remibrutinib, met key...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","BK4578","IE00BJJMRZ35.SGD","01477","PPH","IE0002141913.USD","LU0070302665.USD","IE00B2B36J28.USD","BK4532","BK1574","MEDX","NVS","LU0211331839.USD","LU0320765489.SGD","BK4588","LU0208291251.USD","BK1191","IE0009355771.USD","IE00BJT1NW94.SGD","BK4585","IE00BFTCPJ56.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859981","title":"Ocumension Therapeutics' Application for Ocular Inflammation Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859981","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859981?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:26","pubTimestamp":1788265560,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics'  application for the registration of dexamethasone intraocular suspension was accepted by China's National Medical Products Administration.The product is indicated for the treatment of postoperative ocular inflammation, according to a Tuesday Hong Kong bourse filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","BK1191","LENZ","BK1574","01477","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664856655","title":"Ocumension Therapeutics - Application for Dexamethasone Intraocular Suspension Accepted by Nmpa as Class 4 Chemical Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2664856655","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664856655?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:58","pubTimestamp":1788263929,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":8,"totalSize":257,"code":"91000000","status":"200"}]}}